Direct and Complement Dependent Cytotoxicity in CLL Cells from Patients with High Risk Early Stage Chronic Lymphocytic Leukemia (CLL) Treated with Alemtuzumab and Rituximab

The mechanism of cytotoxicity of alemtuzumab and rituximab in CLL is not well understood. We obtained fresh CLL cells from early stage high risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. Alemtuzumab had minimal direct cytotoxicity b...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zent, Clive S., Secreto, Charla R., LaPlant, Betsy R., Bone, Nancy D., Call, Timothy G., Shanafelt, Tait D., Jelinek, Diane F., Tschumper, Renee C., Kay, Neil E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2588544/
https://ncbi.nlm.nih.gov/pubmed/18584865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.05.014
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares